In this article provided by HealthDay, reporters share results of the VEST Trial (Vest Prevention of Early Sudden Death Trial). According to Dr. Jeffrey Olgin, co-principal investigator of the VEST Trial, “There is a very high risk of death immediately after a heart attack that tails off after about three months.” The VEST Trial was designed to test the benefit of LifeVest use for patients who recently suffered a heart attack and had reduced heart function.
LifeVest is a wearable cardioverter defibrillator (WCD) prescribed to patients at risk of sudden cardiac death (SCD), including those who have a reduced heart function following a heart attack or new diagnosis of heart failure.
Sudden cardiac death (SCD) occurs without warning. The heart’s electrical system controls the heartbeat. When this system fails, it may trigger a dangerously fast heartbeat. This fast heartbeat causes the heart to quiver or shake instead of pumping blood to the body and brain. When this happens, a person can suddenly pass out. Without treatment, death occurs in minutes.
LifeVest monitors the patient's heart continuously, and if the patient goes into a life-threatening heart rhythm, the LifeVest WCD delivers a treatment shock to restore the patient's heart to normal rhythm.